The PAN Foundation Opens New Waldenstrom Macroglobulinemia Patient Assistance Fund


Washington, D.C., (April 2, 2019) - The PAN Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia. Waldenstrom macroglobulinemia is a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.

The American Cancer Society estimates that 1,500 people are diagnosed with Waldenstrom macroglobulinemia each year in the United States. Qualifying patients are eligible to receive grants from PAN to pay for the deductibles, co-pays and coinsurance costs associated with their treatment for Waldenstrom macroglobulinemia.

“The financial impact of a cancer diagnosis can be life-changing for patients and their families,” said PAN President and CEO Daniel Klein. “We know that people living with cancer are often forced to delay or forgo treatment because they cannot afford their out-of-pocket costs. We’re proud to provide financial assistance to patients living with Waldenstrom macroglobulinemia so that they can access the treatments they need and avoid having to make difficult decisions about their health.”

Patients who qualify for the PAN Foundation’s Waldenstrom Macroglobulinemia Assistance Program are eligible to receive $5,000 per year in financial assistance. Eligible patients must be getting treatment for Waldenstrom macroglobulinemia; must reside and receive treatment in the United States; must have Medicare health insurance; and the medication must be covered by their insurance and listed on PAN’s list of covered medications. In addition, patients’ income must fall at or below 500 percent of the Federal Poverty Level.

Patients, or advocates and caregivers applying on their behalf, can apply for assistance using the PAN Foundation’s online patient portal (, or by calling 1-866-316-7263, 9 a.m. to 7 p.m. ET, Monday through Friday. To learn about PAN’s nearly 70 disease-specific programs, visit

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.